Usefulness of Tumor Marker CA-125 Serum Levels for the Follow-Up of Therapeutic Responses in Tuberculosis Patients with and without Serositis
-
- Huang Wei-Chang
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan, ROC
-
- Tseng Chih-Wei
- Division of Gastroenterology, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital, Taiwan, ROC
-
- Chang Kai-Ming
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan, ROC Department of Life Sciences, National Chung Hsing University, Taiwan, ROC
-
- Hsu Jeng-Yuan
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan, ROC
-
- Chen Jiann-Hwa
- Institute of Molecular Biology, National Chung Hsing University, Taiwan, ROC
-
- Shen Gwan-Han
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan, ROC Institute of Molecular Biology, National Chung Hsing University, Taiwan, ROC Department of Respiratory Therapy, China Medical University, Taiwan, ROC
この論文をさがす
抄録
<p>The aim of this study was to determine the usefulness of cancer antigen 125 (CA-125) serum levels in patients with tuberculosis (TB) with and without tuberculous serositis. A total of 64 TB patients with a mean age of 58.17 ± 19.05 years were enrolled in this observational case series study. All patients underwent blood sampling for the measurement of CA-125 serum levels before treatment. If the CA-125 serum levels were found to be elevated, the patients underwent blood sampling in the initial treatment phase, continuation treatment phase, and every 6 months thereafter for 2 years. The treatment outcomes of the pulmonary TB group were evaluated using chest radiography and sputum examinations, and those of the tuberculous serositis group were evaluated on the basis of the amounts of fluid determined by ultrasound. All patients in the tuberculous serositis group and 45% of the patients in the pulmonary TB group had elevated CA-125 serum levels before treatment. The pretreatment mean CA-125 serum level was significantly higher in the tuberculous serositis group than in the pulmonary TB group. CA-125 serum levels decreased along with improvement in anti-TB treatment outcomes in both the groups. In conclusion, the CA-125 serum levels in combination with clinical responses, chest radiography, and sputum examinations, can offer better monitoring of therapeutic responses in anti-TB treatment.<tt> </tt></p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 64 (5), 367-372, 2011-09-30
国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390573242773907328
-
- NII論文ID
- 40019008825
-
- NII書誌ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL書誌ID
- 11254093
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可